ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single‐center clinical utility study—PRECISE study

ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single‐center clinical utility study—PRECISE study

Abstract Introduction In this study (PRECISE), we assess the clinical utility of a germline DNA sequencing‐based test (ToxNav) for mutations in DPYD and ENOSF1 genes to alter clinician‐prescribed fluoropyrimidine doses and the use of a digital application (PROMinet) to record patient‐reported chemot...

Full description

Bibliographic Details
Main Authors: Lennard Y. W. Lee, Thomas Starkey, Shivan Sivakumar, Susan Fotheringham, Guy Mozolowski, Vanessa Shearwood, Claire Palles, Philip Camilleri, David Church, Rachel Kerr, David Kerr
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:Cancer Medicine
Subjects:
chemotherapy
Colorectal cancer
DPYD
ENOSF1
fluoropyrimidine
genetic testing
Online Access:https://doi.org/10.1002/cam4.2529

Internet

https://doi.org/10.1002/cam4.2529

Similar Items